Radioiodine therapy activity 550 MBq of I131 in thyrotoxicosis patients

Background. Radioiodine therapy (RIT) is an alternative method to surgical treatment used in the treatment of hyperthyroidism (Graves’ disease or solitary/multinodular toxic goiter (STG/MTG) etiology). However, treatment protocol doesn’t exist. Aim. To evaluate the outcomes of the I131 treatment in hyperthyroidism using the standard dose (550 Mbq), and to explore the factors that influence the outcome of treatment. Methods. We studied 38 patients (35 women and 3 men) with hyperthyroidism. Each patient was carried I131 RIT in a dose of 550 Mbq. Patients were randomized 2 group – patients with Graves&apos; disease and patients with a solitary/multinodular toxic goiter. Antithyroid drugs withdraw was usually conducted for 7–14 days prior to RIT. Follow-up period ranged from 6 to 8 months, the average was 6.6 ± 0.4 months. Results. Six months after the RIT 23 patients (61%) reached hypothyroidism, 7 patients (18%) was observed euthyroidism, thyrotoxicosis stayed in 8 patients (21%). In patients with Graves&apos; disease onset hypothyroidism were more likely (75% vs 35.7%, p < 0.001). Thus at STG/MTG achieve euthyrosis percentage was higher (28.6% vs 12.5%). Predictors of a positive outcome of the treatment are: less thyroid size (<30 ml for women,